Cardiotrophin-1 - Digna Biotech/Biotecnol

Drug Profile

Cardiotrophin-1 - Digna Biotech/Biotecnol

Alternative Names: CT-1; Recombinant cardiotrophin-1; Recombinant CT-1

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotecnol SA; Digna Biotech; Genentech
  • Developer Biotecnol SA; Digna Biotech
  • Class Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ischaemia; Reperfusion injury
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus; Liver failure

Highest Development Phases

  • Phase II Reperfusion injury
  • Phase I Acute kidney injury
  • No development reported Diabetes mellitus; Ischaemia; Liver failure; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ischaemia(Prevention) in Spain (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-failure in Spain (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top